Regional Bioequivalence Centre for CARICOM, Barbados

Regional Bioequivalence Centre for CARICOM, Barbados
Product Description

Generic manufacturers registering into CARICOM run their bioequivalence studies outside the region or through a small number of bridging facilities elsewhere in the Caribbean. Either route adds cost and schedule to every submission, with in vivo studies running to six figures per product.

BPI's national sector strategy scopes a regional CARICOM bioequivalence centre in Barbados.

We are looking for the partners who would build and operate it: contract research organisations, clinical site partners, and manufacturers who would commit study volume.

Read more Show less

Barbados Pharmaceutical Inc.

  • Country/Region:
    Barbados
  • Founded:
    2023
  • On CPHI since:
    2026
  • Employees:
    1 - 24
Company types
Association/Government
Biopharmaceutical company
Distributor/Import Export
Drug delivery device Supplier/Manufacturer
Finance
Generics/Biosimilars Manufacturer
Innovation cluster
Pharmaceutical company
Wholesale/Retail
Primary activities
API Producer
Biopharmaceutical
Contract Manufacturer
End-product distributor (Wholesale)
Finished Formulation products Distributor/Buyer
Generic APIs producer
Intermediates Manufacturer
Laboratory Services
Medical Devices
Packaging & drug delivery
Pharmaceutical Company (generic finished products)
Supply Chain
View company profile
Categories
more categories Show less
Specifications
  • Details
    • Scope: bioequivalence studies supporting generic product registration
    • Coverage: CARICOM member states
    • Application areas: generic dossier submission, regional registration, post-approval variation
    • Status: scoped in the BPI national sector strategy, partners sought
  • Selling Points
    Place of Origin;
    • Would be the first bioequivalence capability in CARICOM
    • WHO has documented the gap
    • Studies run in the market you are registering into
    • Pairs with Zone IVb stability testing and regulatory pathway work
  • Supplied from
    Barbados
More specifications Fewer specifications
Sales Markets
Show more Show less

Barbados Pharmaceutical Inc.

  • Country/Region:
    Barbados
  • Founded:
    2023
  • On CPHI since:
    2026
  • Employees:
    1 - 24
Company types
Association/Government
Biopharmaceutical company
Distributor/Import Export
Drug delivery device Supplier/Manufacturer
Finance
Generics/Biosimilars Manufacturer
Innovation cluster
Pharmaceutical company
Wholesale/Retail
Primary activities
API Producer
Biopharmaceutical
Contract Manufacturer
End-product distributor (Wholesale)
Finished Formulation products Distributor/Buyer
Generic APIs producer
Intermediates Manufacturer
Laboratory Services
Medical Devices
Packaging & drug delivery
Pharmaceutical Company (generic finished products)
Supply Chain
View company profile

More Products from Barbados Pharmaceutical Inc. (13)

  • Caribbean Natural Products and Marine Bioactives, Barbados

    Product Caribbean Natural Products and Marine Bioactives, Barbados

    The Caribbean has an ethnopharmacological tradition and a marine environment that between them represent an underworked source of natural product candidates.

    BPI's national sector strategy identifies evidence-based traditional and natural products as a long term opportunity area, coverin...
  • CARICOM Market Access and Regulatory Pathway

    Product CARICOM Market Access and Regulatory Pathway

    CARICOM is a set of markets with no single registration route. Manufacturers who could serve the region often do not, because the pathway is unclear and no one market justifies the effort on its own.

    Barbados is building national regulatory capability, and regional review is available th...
  • Digital Systems Partnership for a New GMP Facility, Barbados

    Product Digital Systems Partnership for a New GMP Facility, Barbados

    Most pharmaceutical digital projects are retrofits onto plants that were running before the systems arrived. Barbados is specifying its stack before the facility exists. BPI's national sector strategy sets a digital systems stack of LIMS, ERP and eDMS, compliant with FDA 21 CFR Part 11 and EU Annex...
  • Pharmaceutical Development Base, Barbados

    Product Pharmaceutical Development Base, Barbados

    Place your generic development work in Barbados: stability testing, bioequivalence and reformulation. IP income is taxed at 4.5 per cent, and development spend carries a 50 per cent R&D credit and a 25 per cent productivity and innovation credit.

    Barbados sits in ICH Zone IVb. That matters...
  • Pharmaceutical Manufacturing Investment and Partnership, Barbados

    Product Pharmaceutical Manufacturing Investment and Partnership, Barbados

    BPI was established by the Government of Barbados to build pharmaceutical manufacturing capability and position the country as a production and distribution point for CARICOM and the Global South.

    BPI holds the national pharmaceutical sector strategy. For a manufacturer or investor weigh...
  • Pharmacovigilance and Post-Market Surveillance, Caribbean

    Product Pharmacovigilance and Post-Market Surveillance, Caribbean

    Manufacturers selling into Caribbean markets carry pharmacovigilance and post-market surveillance obligations, with very little capacity in the region to meet them.

    Barbados holds genomic sequencing and molecular diagnostics capacity at the Barbados Living Laboratory, launched at the Best-do...
  • Regional Distribution and Supply into CARICOM

    Product Regional Distribution and Supply into CARICOM

    CARICOM is a set of small markets that most manufacturers treat as not worth serving one country at a time. Aggregated, the demand is real, and the Eastern Caribbean is reached from Barbados.

    PAHO operates its regional public health hub for the Eastern Caribbean from Barbados.
    ...
  • Route to Market: CARICOM and Regional Public Procurement

    Product Route to Market: CARICOM and Regional Public Procurement

    CARICOM is fifteen markets and most manufacturers skip it, because no single one justifies a registration on its own.

    CARPHA's Caribbean Regulatory System reviews a dossier once for the region, which cuts the work per market without removing the national step. Two buyers carry the volume: the ...
  • Stability Testing, ICH Zone IVb (30°C / 75% RH), Barbados

    Product Stability Testing, ICH Zone IVb (30°C / 75% RH), Barbados

    Products registered across the Caribbean, Brazil, India and the ASEAN markets require stability data generated at ICH Zone IVb conditions, 30°C ±2°C and 75% relative humidity ±5%. Data from a European laboratory at 25°C and 60% RH will not satisfy those regulators.

    Barbados sits in Zone I...
  • Sterile Manufacturing Partnership, Barbados

    Product Sterile Manufacturing Partnership, Barbados

    BPI's joint venture with AMA delivered its first shipment of intravenous solutions to Barbados in March 2026, imported from Nigeria while local manufacturing is built. This would be the first sterile capability in the country. 

    BPI holds the national pharmaceutical sector strategy...
  • Technology Transfer and Contract Manufacturing Partnership, Barbados

    Product Technology Transfer and Contract Manufacturing Partnership, Barbados

    BPI is building pharmaceutical formulation capacity in Barbados and is looking for technology transfer partners: established manufacturers with proven products and processes seeking a production base for CARICOM and the Global South.

    BPI's transfer framework covers 5 components: f...
  • Tropical and Paediatric Reformulation, Barbados

    Product Tropical and Paediatric Reformulation, Barbados

    A formulation that performs in a temperate market does not automatically perform in a tropical one. Products registered into Zone IVb markets face 30°C and 75% relative humidity as a baseline storage condition, and reformulation is often the difference between a viable shelf life and a failed submissio...
show all 13 other products